Home
/
Lyell Immunopharma, Inc.
/
Financials
/
Quarterly
Lyell Immunopharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Lyell Immunopharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$15.0K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$8.0K
Aug 12, 2025
Q1
2025
Mar 31, 2025
$7.0K
May 13, 2025
Q3
2025
Sep 30, 2024
$34.0K
Nov 12, 2025
Q2
2025
Jun 30, 2024
$13.0K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$3.0K
May 13, 2025
Q3
2024
Sep 30, 2023
$25.0K
Nov 7, 2024
Q2
2024
Jun 30, 2023
$27.0K
Aug 7, 2024
Q1
2024
Mar 31, 2023
$65.0K
May 6, 2024
Q3
2023
Sep 30, 2022
$3.0K
Nov 7, 2023
Q2
2023
Jun 30, 2022
$35.74M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$553.0K
May 4, 2023
Q3
2022
Sep 30, 2021
$2.76M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$2.63M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$2.45M
May 10, 2022
Q3
2021
Sep 30, 2020
$1.07M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$3.12M
Aug 12, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($38.85M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($42.68M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($52.20M)
May 13, 2025
Q3
2025
Sep 30, 2024
($44.58M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($45.81M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($60.67M)
May 13, 2025
Q3
2024
Sep 30, 2023
($50.85M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($63.89M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($66.96M)
May 6, 2024
Q3
2023
Sep 30, 2022
($70.25M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($36.32M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($68.14M)
May 4, 2023
Q3
2022
Sep 30, 2021
($48.88M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($62.60M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($55.04M)
May 10, 2022
Q3
2021
Sep 30, 2020
($35.72M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($100.66M)
Aug 12, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($37.25M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($47.14M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($57.37M)
May 13, 2025
Q3
2025
Sep 30, 2024
($50.51M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($51.53M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($55.58M)
May 13, 2025
Q3
2024
Sep 30, 2023
($59.04M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($65.91M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($62.56M)
May 6, 2024
Q3
2023
Sep 30, 2022
($66.44M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($37.26M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($68.58M)
May 4, 2023
Q3
2022
Sep 30, 2021
($49.16M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($62.71M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($55.37M)
May 10, 2022
Q3
2021
Sep 30, 2020
($36.84M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($102.57M)
Aug 12, 2021